Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-05-10
2011-05-10
Landsman, Robert (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S141100, C424S145100, C435S335000, C530S388100, C530S388230
Reexamination Certificate
active
07939637
ABSTRACT:
Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.
REFERENCES:
patent: 6632927 (2003-10-01), Adair et al.
patent: 2006/0193772 (2006-08-01), Ochiai et al.
patent: 492552 (1992-07-01), None
patent: 1 505 075 (2005-09-01), None
patent: WO 02/053596 (2002-07-01), None
patent: WO 03/93317 (2003-11-01), None
patent: 2005/016970 (2005-02-01), None
patent: WO 2005/018671 (2005-03-01), None
patent: WO 2005/028515 (2005-03-01), None
patent: 2007/022172 (2007-02-01), None
Holliger et al., Engineered antibody fragments and the rise of single domains, 2005, Nature Biotechnology, vol. 23, Issue 9, pp. 1126-1136.
Amit et al., 1986, Science, vol. 233, No. 4765, pp. 747-753.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 3080-3084.
Rudikoff et al., 1982, Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1979-1983.
Benini et al.Clin. Cancer Res. 7:1790-1797 (2001).
Burtrum et al.Cancer Res. 63:8912-8921 (2003).
Cohen et al.Clin. Cancer Res. 11:2063-2073 (2005).
Garcia-Echeverria et al.Cancer Cell. 5:231-239 (2004).
Goetsch et al.Int. J. Cancer. 113:316-328 (2005).
Goya et al.Cancer Res. 64:6252-6258 (2004).
Hailey et al.Mol. Cancer Ther. 1:1349-1353 (2002).
Maloney et al.Cancer Res. 63:5073-5083 (2003).
Mitsiades et al.Cancer Cell. 5:221-230 (2004).
Miyamoto et al.Clin. Cancer Res. 11(9):3494-3502 (2005).
Sachdev et al.Cancer Res. 63:627-635 (2003).
Wu et al.Cancer Res. 63:4384-4388 (2003).
Yakar et al.Proc. Natl. Acad. Sci. USA. 96:7324-7329 (1999).
Enjoh T et al, Characterization of New Monoclonal Antibodies to Human Insulin-Like Growth Factor-II and Their Application in Western Immunoblot Analysis, Journal of Clinical Endocrinology and Metabolism, 1993, 510-517, 77.
Manes S et al, Functional Epitope Mapping of Insulin-Like Growth Factor I (IGF-I) by Anti-IGF-I Monoclonal Antibodies, Endocrinology, 1997, 905-915, 138.
Russel W E et al, Inhibition of the mitogenic effects of plasma by a monoclonal antibody to stomatomedin C, Proceedings of the national academy of science, 1984, 2389-2392, 81.
Van Wuk Judson J et al, Molecular Basis for Species and Ligand Specificity of a Monoclonal Antibody Raised Against Human IGIF-I, Endocrinology, 1997, 4521-4523, 138.
Cartlidge Susan A et al, MEDI-573-A fully human antibody to IGF-I and IGF-II for the treatment of solid tumor and hematological diseases, American Association for Cancer Research 100th Annual Meeting, Denver, Apr. 2009.
International Search Report, PCT/ISA/210, WIPO, Apr. 2005.
Masaharu Takigawa et. al, “Insulin-Like Growth Factors I and II Are Autocrine Factors in Stimulating Proteoglycan Synthesis, a Marker of Differentiated Chondrocytes,Acting through Their Respective Receptors on a Clonal Human Chondrosarcoma-Derived Chondrocyte Cell Line, HCS-2/8”, Endocrinology, vol. 138,No. 10, pp. 4390-4400, 1997.
Raffaele Zarrilli et al., “Constitutive Insulin-like Growth Factor-II Expression Interferes with the Enterocyte-like Differentiation of CaCo-2 Cells”, The Journal of Biological Chemistry,vol. 271, No. 14, pp. 8108-8114,1996.
Blakey David, Development of a Portfolio of Antibody Based Therapeutics for Cancer Therapy, ELRIG (2009) European Laboratory Robotics Interest Group—Drug Discovery 2009, Sep. 7-8, 2009, Liverpool, UK, (presentation).
Blakey David, Development of a Portfolio of Antibody Based Therapeutics for Oncology, Pre-Clinical/Clinical Development of Therapeutic Antibodies, PEGS (2009) Protein Engineering Summit—5th Annual, Apr. 6-7, 2009, Boston, (presentation).
Blakey David, Development of novel human therapeutic antibodies targeting the IGF and PDGF signalling pathways for cancer therapy, ICRA (2009) International Congress on Recombinant Antibodies—Jun. 8, 15-19, 2009, Cologne, (presentation).
Blakey David, Identification and preclinical anti-tumour activity of human antibodies targeting growth factor and angiogenic ligands, WBF (2009) World Biopharm Forum—Cancer Biologics and Therapy, (presentation).
Bosslet K. et al., The Development of Therapeutic antibodies for Cancer Therapy, VP Oncology Research MedImmune, Bio (2009) Bionnale, Apr. 29, 2009(presentation).
Cartlidge S. et al., A fully human antibody to IGF-I and IGF-II for the treatment of solid tumour and haematological diseases, AACR (2009) American Association for Cancer Research—100th Annual Meeting.
Cheesebrough et al., In vivo pharmacology of MEDI-573, an anti-IGF-I and IGF-II antibody that targets the IGF-1R and IR-A signaling pathways, AACR (2009) American Association for Cancer Research—100th Annual Meeting, Apr. 18-22, 2008, Denver, CO.
Zusmanovich M et al., A Pharmacokinetic/Pharmacodynamic Study of Medi-573, a Fully Human IgG2 Monoclonal Antibody against Insulin-like Growth Factors, in Male Cynomolgus Monkeys Following Intravenous Administration, AAPS (2009) American Association of Pharmaceutical Scientists—2009 Annual Meeting & Exposition, Nov. 8-12, 2009, Los Angeles, CA, (presentation).
Cartlidge Susan Ann
Gazit-Bornstein Gadi
Raeber Olivia
Tonge David William
Yang Xiao-dong
Dang Ian
Landsman Robert
MedImmune
MedImmune Limited
LandOfFree
Insulin-like growth factor antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665383